Exosome Diagnostics, PCF Partner to Improve Prostate Cancer Dx Technologies | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exosome Diagnostics and the Prostate Cancer Foundation today announced a multi-year collaboration to assess the capabilities of RNA biofluid diagnostics for the detection of prostate cancer and to accelerate clinical validation of Exosome's technology for the disease.

The partnership will evaluate new RNA biofluid diagnostics for the early detection, progression monitoring, and advanced disease risk stratification in prostate cancer, Exosome and PCF said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.